Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer

BACKGROUND: The mammalian target of rapamycin inhibitor everolimus is approved as an antitumor agent in advanced estrogen receptor-positive breast cancer. Surrogate bone marker data from clinical trials suggest effects on bone metabolism, but the mode of action of everolimus in bone biology remains...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res
Main Authors: Browne, Andrew J., Kubasch, Marie L., Göbel, Andy, Hadji, Peyman, Chen, David, Rauner, Martina, Stölzel, Friedrich, Hofbauer, Lorenz C., Rachner, Tilman D.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5551016/
https://ncbi.nlm.nih.gov/pubmed/28793923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-017-0885-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados